Vir Biotechnology Inc
Vir Biotechnology Inc (VIR) Unusual Options Activity Today
VIR options volume power reached 1x on the previous trading day. The highest reading was on the $7 PUT expiring 2027-01-15.
Read more
Checking VIR unusual options activity helps you spot when traders are making outsized bets on Vir Biotechnology Inc before the broader market catches on. Vir Biotechnology Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor VIR unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching VIR unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking VIR unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and VIR unusual options flow data becomes especially valuable around earnings, product launches, and macro events.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Catalysts rarely arrive without a footprint, and VIR unusual options activity is often where that footprint shows up first. Our scanner tracks Vir Biotechnology Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at VIR unusual options volume on the call side or chasing put sweeps, Vir Biotechnology Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.
| 13.00 | — | 0.60 | 0.60 | 112% | 5 | 289 | 1.73% |
| 12.00 | 0.30 | 0.50 | 0.40 | 66% | 1 | 140 | 0.71% |
| 1.00 | 9.00 | 12.00 | 10.50 | 946% | 0 | 0 | — |
| 2.00 | 7.10 | 11.50 | 9.30 | 505% | 0 | 0 | — |
| 3.00 | 6.10 | 10.50 | 8.30 | 385% | 0 | 3 | 0.00% |
| 1.00 | — | 0.05 | 0.05 | 530% | 0 | 5 | 0.00% |
| 2.00 | — | 0.05 | 0.05 | 371% | 0 | 0 | — |
| 3.00 | — | 0.95 | 0.95 | 662% | 0 | 0 | — |
| 4.00 | — | 2.00 | 2.00 | 797% | 0 | 1 | 0.00% |
| 5.00 | — | 2.20 | 2.20 | 682% | 0 | 16 | 0.00% |
As of September 28, 2026
Spot unusual options activity before it moves
Track VIR options flow across every expiration, filter by volume power, and find the setups with abnormal activity before the trade is gone.
Start your 14-day free trial→